Market's view on Ixico
Published on April 2024
- Stock watchers discuss the critical cash drawdown highlighted in a recent trading update, indicating it might lead to a capital raise.
- Concerns are raised about the CEO’s effectiveness and cost, with suggestions for a replacement to reduce overheads and possibly restructure the company’s strategy.
- Discussion on the need for significant new contracts or reductions in R&D spending to avoid further cash requirements.
- Frustration is voiced over the company’s current valuation and management’s performance during investor calls, suggesting a lack of interest and initiative from the current CEO.
- Criticism of the company’s board and management, describing them as overpaid and underqualified, with a call for cost-cutting and a refocused R&D strategy.
- Observations made on the company’s inability to secure significant contracts in the Alzheimer’s disease space, which is crucial for growth but remains a challenging area to penetrate.
- Stock watchers express disappointment over the company’s revenue forecasts, expecting flat growth and continued losses without substantial contract wins.
- Discussions indicate a possible need for market surveillance contracts in Alzheimer’s disease post-FDA approvals, which could be a critical opportunity for the company.
- General consensus on the company’s poor share price performance and potential vulnerability to a takeover due to its low valuation.